Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin
Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin
复制标题
使用利妥昔单抗和 brentuximab vedotin 治疗的具有 T 辅助表型的复合弥漫性大 B 细胞和外周 T 细胞淋巴瘤
DOI：
10.1007/s00277-021-04633-6
复制
发表时间：
2021
影响因子：
3.5
通讯作者：
Tajima Katsushi
中科院分区：
文献类型：
--
作者：
Ohya Kouichi;Okuyama Shuhei;Ogata Shin-ya;Maeda Kunihiko;Yamada Kyohei;Ohshima Kouichi;Tajima Katsushi
复合淋巴瘤(CL)被定义为单个解剖组织或同一淋巴结中存在两种或多种不同的淋巴瘤亚型，而不一致淋巴瘤是两种或多种不同的淋巴瘤亚型同时存在于不同部位[1]。 T/B 细胞型 CL 相当罕见 [2]。 T/B细胞型CL的最佳或标准治疗尚未确定。 一位80岁的日本女性，10年前患有骨髓增生异常综合征伴多系发育不良，定期来我院就诊，但未接受任何治疗。她的定期检查发现全身淋巴结（LN）肿大，不久之后，她出现了几个皮下结节。实验室检查结果如下：WBCs，2220/μL；血红蛋白，11.8 克/分升； 96,000 英镑；可溶性 IL-2 受体，4170 U/mL（正常值 121–613）。正发射断层扫描/计算机断层扫描（PET-CT）显示淋巴结和皮下结节的代谢活动增加（图1a）。锁骨上淋巴结活检显示扩大的滤泡间区域存在中型至大型异常淋巴细胞和内皮细胞的弥漫性增殖（图 1b、c）。滤泡间区域的中等大小细胞 CD3、PD-1、ICOS、CXCL13 和 BC-6 呈阳性，但 CD10 呈阴性（图 1d、e）。这
Composite lymphoma (CL) is defined as two or more distinct lymphoma subtypes in a single anatomic tissue or the same lymph node, while discordant lymphoma is two or more distinct lymphoma subtypes existing at different sites simultaneously [1]. The T-/B-cell type CL is quite rare [2]. Optimal or standard treatments for T-/B-cell type CLs have not yet been defined.An 80-year-old Japanese woman, who had myelodysplastic syndrome with multilineage dysplasia 10 years ago, visited our hospital regularly without any treatments. Her regular examination identified systemic lymph node (LN) enlargements, and after a short time, she developed several subcutaneous nodules. Laboratory findings were as follows: WBCs, 2220/μL; hemoglobin, 11.8 g/dL; Plts, 96,000; soluble IL-2 receptor, 4170 U/mL (normal 121–613). Positronemission tomography/computed tomography (PET-CT) showed increased metabolic activity in the LNs and subcutaneous nodules (Fig. 1a). A supraclavicular LN biopsy revealed the diffuse proliferation of medium to large abnormal lymphoid cells and endothelium in expanded interfollicular areas (Fig. 1b, c). The medium-sized cells in the interfollicular areas were positive for CD3, PD-1, ICOS, CXCL13, and BC-6, but negative for CD10 (Fig. 1d, e). The
涉及淋巴结的 T 细胞淋巴瘤分类的建议免疫组织化学算法。
影响因子：
3.3
作者：
F. Vega;L. J. Medeiros
通讯作者：
L. J. Medeiros